EP1161542A1 - Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans - Google Patents
Elongase d'acides gras polyinsatures tires de caenorhabiditis elegansInfo
- Publication number
- EP1161542A1 EP1161542A1 EP00911091A EP00911091A EP1161542A1 EP 1161542 A1 EP1161542 A1 EP 1161542A1 EP 00911091 A EP00911091 A EP 00911091A EP 00911091 A EP00911091 A EP 00911091A EP 1161542 A1 EP1161542 A1 EP 1161542A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- pufa
- acid
- polypeptide according
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000194 fatty acid Substances 0.000 title claims description 38
- 235000014113 dietary fatty acids Nutrition 0.000 title claims description 28
- 229930195729 fatty acid Natural products 0.000 title claims description 28
- 150000004665 fatty acids Chemical class 0.000 title description 21
- 241000244203 Caenorhabditis elegans Species 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 229920001184 polypeptide Polymers 0.000 claims abstract description 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 24
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 10
- -1 carbon fatty acid Chemical class 0.000 claims description 10
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000009261 transgenic effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000037361 pathway Effects 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 6
- 241000206602 Eukaryota Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 238000007792 addition Methods 0.000 claims description 5
- 235000021342 arachidonic acid Nutrition 0.000 claims description 5
- 229940114079 arachidonic acid Drugs 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- WBBQTNCISCKUMU-PDBXOOCHSA-N (13Z,16Z,19Z)-docosatrienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCCCC(O)=O WBBQTNCISCKUMU-PDBXOOCHSA-N 0.000 claims description 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 2
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims description 2
- 239000004606 Fillers/Extenders Substances 0.000 claims description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 2
- 230000037429 base substitution Effects 0.000 claims description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003028 elevating effect Effects 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 26
- 108700026244 Open Reading Frames Proteins 0.000 description 24
- 239000000758 substrate Substances 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 19
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 19
- 108010058732 Fatty Acid Elongases Proteins 0.000 description 18
- 101100118654 Caenorhabditis elegans elo-1 gene Proteins 0.000 description 17
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 17
- 102000036181 Fatty Acid Elongases Human genes 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 210000000349 chromosome Anatomy 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000003408 sphingolipids Chemical class 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000219194 Arabidopsis Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 101100011518 Arabidopsis thaliana ELP1 gene Proteins 0.000 description 3
- 101100172211 Arabidopsis thaliana HAG3 gene Proteins 0.000 description 3
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100501248 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO2 gene Proteins 0.000 description 3
- 101100501251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO3 gene Proteins 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 2
- 241001072256 Boraginaceae Species 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102100020754 Putative fatty acid desaturase 2-like protein FADS2B Human genes 0.000 description 2
- 101100118655 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO1 gene Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000021322 Vaccenic acid Nutrition 0.000 description 2
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 108010009106 sphingolipid desaturase Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- LGHXTTIAZFVCCU-SSVNFBSYSA-N (2E,4E,6E,8E)-octadeca-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O LGHXTTIAZFVCCU-SSVNFBSYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 102000052553 3-Hydroxyacyl CoA Dehydrogenase Human genes 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 101100225658 Arabidopsis thaliana ELP4 gene Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 101000848256 Danio rerio Acyl-CoA 6-desaturase Proteins 0.000 description 1
- 241000132179 Eurotium medium Species 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 1
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000848282 Siganus canaliculatus Acyl-CoA Delta-6 desaturase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000221013 Viscum album Species 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 108010060641 flavanone synthetase Proteins 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to polyunsaturated fatty acid (PUFA) elongases. More specifically, the invention relates to a DNA sequence from C. elegans encoding a PUFA elongase.
- PUFA polyunsaturated fatty acid
- Unsaturated fatty acids are essential components required for normal cellular function, being involved in a diverse number of roles ranging from membrane fluidity to acting as signal molecules (Gill, I., Valivety, R. (1997). Trends Biotechnol. 15, 401-409; Broun, P., et al (1999) Ann. Rev. Nutr. 19, 197-216).
- the class of fatty acids known as the polyunsaturated fatty acids (PUFAs) has attracted considerable interest as pharmaceutical and nutraceutical compounds (Broun supra; Horrobin, D. F. (1990) Reviews in Contemp Pharmacotherpy 1, 1-45).
- PUFAs i.e. fatty acids of 18 carbons or more in length and containing two or more double bonds
- This elongase is responsible for the addition of 2 carbon units to an 18 carbon PUFA, resulting in a 20 carbon fatty acid.
- This reaction is the elongation of ⁇ -linolenic acid (GLA; 18:3 ⁇ 6,9 12 ) to di-homo- ⁇ -linolenic acid (DHGLA; 20:3 ⁇ 8,11 ' 14 ) in which the tri-unsaturated 18 carbon fatty acid is elongated by the addition of a two carbon unit to yield the tri-unsaturated 20 carbon fatty acid. Since there is considerable interest in the production of long chain PUFAs of more than 18 carbons in chain length, for example arachidonic acid and eicosapentanoic acid, the identification of this enzyme is of both academic and commercial interest.
- an Arabidopsis gene (FAE1) has been shown to be required for the synthesis of very long chain monounsaturated fatty acids (such as erucic acid; 20:l ⁇ ⁇ ) (James, D. W. et al, (1995) Plant Cell 7, 309-319).
- this enzyme does not recognize di- and tri-unsaturated 18 carbon fatty acids, for example, linoleic acid, 18:2 ⁇ 9 ' 12 or ⁇ -linolenic acid, 18:3 ⁇ 9 ' 2 ' 5 respectively, as substrates, and is therefore not involved in the synthesis of long chain PUFAs (Millar & Kunststoff (1997), Plant Journal 12, 121-131).
- FIG. 1 A schematic diagram representing a generalized pathway for the product of PUFAs is shown in Figure 1.
- Biochemical characterisation of mammalian elongation systems has indicated that a mammalian elongase consists of four subunits, made up of a condensing enzyme, a ⁇ -ketoreductase, a dehydrase and an enoyl reductase (reviewed in Cinti, D. L., et al (1992) Prog. Lipid Res. 31, 1-51).
- the Arabidopsis FAEl gene product encodes a polypeptide of 56kDa, which shows very limited homology to condensing enzymes such as chalcone synthase and stillbene synthase (James, D. W. supra). Although FAEl is normally only expressed in seed tissues, ectopic expression in non-seed tissue (or heterologously in yeast) revealed that FAEl could direct the synthesis of erucic acid (Millar, A. A., Kunststoff, L. (1997) Plant J. 12, 121-131).
- ELO1 Three fatty acid elongase activities have been characterised from the yeast S. cerevisiae. Again, this organism does not synthesis PUFAs, and therefore does not contain genes encoding a PUFA elongase.
- One gene ELO1 was identified on the basis of a screen to isolate mutants defective in elongation of 14 carbon (i.e. medium) chain saturated fatty acids (Toke & Martin (1996) J Biol Chem 271, 18413-18422). Complementation of elol mutants restored viability, and the ELO1 gene product was shown to encode a polypeptide which was responsible for the specific elongation of 14:0 fatty acids to 16:0 fatty acids.
- ELO2 and ELO3 Two related genes were also detected in the genome of S. cerevisiae, and their function determined by disruption. These two genes, subsequently named ELO2 and ELO3, were shown to be involved in the elongation of the very long chain saturated fatty acids found in sphingolipid molecules (Oh et al (1997), J. Biol Chem 272, 17376-17384). In particular, ELO2 was required for elongation of fatty acids up to 24 carbons, and ELO3 was required for elongation of the 24 carbon fatty acid to 26 carbons. However, neither gene was essential for viability.
- elegans like most other animals, and in contrast to higher plants, synthesises PUFAs such as arachidonic acid (AA; 20:4 A 5,8 11,14 ) as precursors to a class of molecules known as the eicosanoids, which in turn serve as precursors for compounds such as prostaglandins and leucotrienes (Horrobin, (1990), Reviews in Contemp Pharmacotherpy, 1:1-45).
- AA arachidonic acid
- eicosanoids which in turn serve as precursors for compounds such as prostaglandins and leucotrienes
- Horrobin (1990), Reviews in Contemp Pharmacotherpy, 1:1-45.
- the presence of AA and other long chain polyunsaturated fatty acids in C. elegans is well documented (Tanaka et al, (1996), Lipids 31, 1173-1178).
- the complete sequence of the nematode's genome is now publicly available (The C. elegans consortium, 1998, Science
- An object of the invention is to provide an isolated PUFA elongase.
- ORFs putative open reading frames
- a first aspect of the invention provides an isolated polypeptide comprising a functional long chain polyunsaturated fatty acid (PUFA) elongase i.e. the polypeptide has the function of extending the chain length of an 18 carbon PUFA to 20 carbons in length.
- PUFA long chain polyunsaturated fatty acid
- the polypeptide may be from a eukaryote.
- the polypeptide may comprise at least a portion of the amino acid shown in SEQ LD. 15, or variants thereof.
- variants in relation to a certain sequence means a protein or polypeptide which is derived from the sequence through the insertion or deletion of one or more amino acid residues or the substitution of one or more animo acid residues with amino acid residues having similar properties, e.g. the replacement of a polar amino acid residue with another polar amino acid residue, or the replacement of a non-polar amino acid residue with another non-polar amino acid residue.
- variants must have an elongase function as defined herein.
- a second aspect of the invention provides a polypeptide having at least 60 % homology to a polypeptide according to a first aspect of the invention.
- the polypeptide may have at least 80%), or as much as 90% or more homology to a polypeptide according to a first aspect of the invention.
- the polypeptide according to either aspect of the invention may include a sequence motif responsible for Endoplasmic Reticulum (ER) - retention. This allows the polypeptide to be specifically located or targeted to the ER of a cell.
- ER Endoplasmic Reticulum
- the polypeptide may also be able to elongate palmitoleic acid (PA; 16:1 ⁇ 9 ) to vacceric acid (VA; 18:l ⁇ n ).
- PA palmitoleic acid
- VA vacceric acid
- the polypeptide is also capable of elongation of a ⁇ 9 - monounsaturated 16C fatty acid.
- the polypeptide is from an animal, more preferably, the animal is an invertebrate such as a worm. Where the animal is a worm, it is preferably C. elegans. Alternatively, the animal is a vertebrate, preferably a mammal such as a human, rat or mouse.
- a third aspect of the invention provides an isolated DNA sequence, preferably a cDNA sequence, encoding a polypeptide according to a first or second aspect of the invention. This DNA sequence may be used to engineer transgenic organisms.
- the DNA sequence comprises the sequence shown in SEQ ID NO: 7 or variants of that sequence due, for example, to base substitutions, deletions, and/or additions.
- a fourth aspect of the invention provides an engineered organism, such as a transgenic animal, engineered to express a polypeptide according to a first or second aspect of the invention.
- the engineered organism may be engineered to express elevated levels of the polypeptide, thereby providing a supply of polypeptide at a reduced cost as a reduced number of organisms need be used.
- the engineered organism is a mammal such as a rat, mouse or monkey.
- a fifth aspect of the invention provides an engineered organism containing a synthetic pathway for the production of a polypeptide according to a first or second aspect of the invention. This has the advantage of allowing greater control over the production of PUFAs by the pathway by an organism.
- the pathway may include ⁇ -fatty acid desaturase, and/or ⁇ 6 -fatty acid desaturase.
- the engineered organism according to a fourth or fifth aspect of the invention may be a lower eukaryote, such as yeast.
- the transgenic organism may be a fish.
- a sixth aspect of the invention provides a transgenic plant engineered to express a polypeptide according to a first aspect of the invention.
- a seventh aspect of the invention provides a transgenic plant containing a DNA sequence according to a third aspect of the invention.
- An eighth aspect of the invention provides a method of producing a PUFA comprising carrying out an elongase reaction catalysed by a polypeptide according to a first or second aspect of the invention.
- the PUFA may be di-homo-gamma-linoleic acid (20:3 ⁇ 8 11 14 ), arachidonic acid (20:4 ⁇ SA, U4 ), eicosapentanoic acid (20:5 ⁇ 5A11 14 17 ), docosatrienoic acid (22:3 ⁇ 3 16 19 ), docosatetraenoic acid (22:4 ⁇ 7,10 ' 13 ' 16 ), docosapentaenoic acid (22:5 ⁇ 7 10 ' 13 ' 16 ' 19 ) or docosahexaenoic acid (22:6 ⁇ 4 ' 7 - 10 13 16 19 ).
- the PUFA may be a 24 carbon fatty acid with at least 4 double bonds.
- a ninth aspect of the invention provides a PUFA produced by a method according to an eighth aspect of the invention.
- the PUFA may be used in foodstuffs, dietary supplements or pharmaceutical compositions.
- a tenth aspect of the invention provides a foodstuff comprising a PUFA according to a fifth aspect of the invention.
- the foodstuff can be fed to an animal.
- An eleventh aspect of the invention provides a dietary supplement comprising a PUFA according to a fifth aspect of the invention.
- the dietary supplement can be supplied to an animal to augment its PUFA levels.
- An twelfth aspect of the invention provides a pharmaceutical composition comprising a polypeptide according to a first or second aspect of the invention or a PUFA according to a ninth aspect of the invention.
- the pharmaceutical composition comprises a pharmaceutically-acceptable diluent, carrier, excipient or extender.
- a topical application would preferably be a cream or lotion, whereas if the composition was to be ingested a different form would be more suitable.
- a thirteenth aspect of the invention provides a method of treatment of an animal, such as a mammal, or a plant, comprising supplying to the animal or plant a DNA sequence according to a third aspect of the invention, a foodstuff according to a tenth aspect of the invention, a dietary supplement according to an eleventh aspect of the invention, a pharmaceutical composition according to a twelfth aspect of the invention or a PUFA according to a ninth aspect of the invention.
- the mammal is a human.
- SEQ LDl to 8 show the putative ORFs encoding PUFA elongases A to H respectively;
- SEQ ID9 to 16 show the deduced amino acid sequences of the putative ORFs of SEQ ID NO: 1 to 8 respectively;
- Figures 2 to 9 show hydrophobicity plots for each of PUFA elongases A to H respectively.
- Figure 10 shows an amino acid sequence line-up comparing the C. elegans ORF F56H1 1.4 (Z68749) with related sequences.
- Figure 11 shows chromatograms of fatty acid methyl esters from transformed yeast.
- C. elegans databases were searched for any sequences which showed low levels of homology to yeast ELO genes (EL02 and EL03) using the TBLASTN programme.
- a similar search was carried out using short (20 to 50 amino acid) stretches of ELO genes which were conserved amongst the three ELO polypeptide sequences.
- C. elegans sequences which were identified by this method were then used themselves as search probes, to identify any related C. elegans genes which the initial search with the yeast sequences failed to identify. This was necessary because the level of homology between the yeast ELO genes .and any worm genes is always low (see BLAST scores later).
- GenBank is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences (Nucleic Acid Research (1998) 26, 1-7). There are approximately 2,162,000,000 bases in 3,044,000 sequence records as of December 1998.
- Wormpep contains predicted proteins from the Caenorhabditis elegans genome sequence project, which is carried out jointly by the Sanger Centre in Cambridge, UK and Genome Sequencing Center in St. Louis, USA.
- the current Wormpep database, Wormpep 16 contains 16,332 protein sequences (7,120,115 residues). Search strings used included [HXXHH], [HXXXHH], [QXXHH] and [YHH]. Comparison of the data from the two different searches indicated a small ( ⁇ 10) number of putative ORFs as candidate elongases.
- the histidine box motifs are shown in bold in SEQ ID 9 to 16.
- fatty acid elongases are expected to be endoplasmic reticulum (ER) membrane proteins, they might be expected to have peptide signals which are responsible for "ER-retention".
- this signal often takes the form of a C-terminal motif [K-K-X 2 -3-Stop], or similar variants thereof (Jackson et al, (1990), EMBO J., 9, 3153-3162). Further sequence analysis of the C.
- C. elegans genes involved in the synthesis of PUFA may exist in tandem (for example the ⁇ 5 and ⁇ 6 desaturases required for AA and GLA synthesis, respectively, are ⁇ 1 kB apart on chromosome IN (Michaelson et al, (1998), FEBS Letts 439, 215-218), the positions of the putative C. elegans elongase ORFs were determined using the Sanger Centre's WebAce C. elegans server (http://www.sanger.ac.uk/Projects/C_elegans/webace_front_end.shtml). This indicated that two pairs of putative elongases were in close proximity to each other on the C. elegans chromosome IV.
- F41H10.7 and F41H10.8 were identified as being approximately 10 Kb apart on chromosome IV, and F56H11.3 and F56H11.4 were identified as being approximately 2 Kb apart on chromosome IV.
- the positions of the putative ORFs in the C. elegans genome are shown below i.e. chromosome number, and map position in centiMorgans, together with the GenBank database accession numbers.
- ORF C40H1.4 is predicted coding sequence 4 on cosmid C40H1.
- Each of the three yeast ELO polypeptides were compared against all of the worm putative elongase tr.anslated ORF sequences, and then ranked in order of similarity (as measured by the BLAST score) (Altschul et al (1990), supra)
- Yeast ELO 1 (14 to 16 carbon fatty acid elongase)
- C. elegans ⁇ 5 and ⁇ 6 fatty acid desaturases have evolved from 1 ancestral gene (Michaelson et al, (1998), FEBS Letts 439, 215-218). It is also significant that one pair of C. elegans putative elongase ORFs (F & G) genetically maps close to the ⁇ 5/ ⁇ 6 fatty acid desaturase genes, with both gene pairs being located at the top end of chromosome IV.
- F56H11.4 and F41H10.8 were cloned by PCR into the pYES2 vector (Invitrogen).
- a C. elegans mixed stage cDNA library was used as a PCR template.
- F56H11.4 was amplified using primers:
- Amplified sequences were then restricted using Kpnl and BamHI (underlined in the forward and reverse primers, respectively), purified using the Qiagen PCR purification kit, and ligated into a Kpnl/BarnHI cut pYes2 vector.
- Elongases and desaturase constructs were introduced in Saccharomyces cerevisiae W303-1A using a lithium acetate based method (Elble, R. (1992) Biotechniques 13, 18-20) and expression of the transgenes was induced by addition of galactose to 2% (w/v) as described in Napier et al (Napier, J. A., et al (1998) Biochem J 330, 611-614; Michaelson L. V., supra; Michaelson, L. V., (1998) FEBS Letts 439, 215-218).
- Yeast transformants containing pYES2-derived constructs were grown on synthetic minimal media (SD, the composition of which is defined in Sherman, F (1991) Methods in Enzymology 194, 3-21); synthetic minimal medium minus uracil; pESC-derived constructs were grown on SD minimal medium minus tryptophan.
- Co-transformed yeast (containing both pYES2 and pESC derivatives) were grown on SD minimal medium minus uracil and tryptophan.
- cultures Prior to induction, cultures were grown in the presence of 2% raffmose and supplemented with 0.5 mM of the appropriate fatty acid substrate in the presence of 1% tergitol-(NP40) (Sigma). All cultures were then grown for a further 48-h unless indicated.
- Lipids were extracted from transformed and control yeast by homogenisation in MeOH-CHCl 3 using a modification of the method of Bligh and Dyer (Dickenson & Lester (1999) Biochim Biophys Acta 1426, 347-357).
- the resulting CHCL phase was evaporated to dryness under nitrogen gas and the samples were transmethylated with 1M HC1 in methanol at 80 °C for 1 hour.
- Fatty acid methyl esters (FAMES) were extracted in hexane and purified using a small column packed with Florisil.
- fatty acids extracted from yeast cultures were analysed by gas chromatography (GC) of methyl ester derivatives. Lipids were extracted, transmethylated and the fatty acid methyl esters (FAMEs) analysed as described by Sayanova et al.
- GC gas chromatography
- Figure 11 shows chromatograms of fatty acid methyl esters from yeast transformed with the control (empty) plasmid pYES2 (Fig. 11 A) or with ORF F56H11.4 in pYES2 (Fig. 11B). Exogenous substrate in the form of GLA was supplied to the cultures. Two novel peaks are observed in (B); these peaks (annotated as 20:3 and 18: 1 *) were identified (against known standards) as DHGLA and vaccenic acid, respectively. Detection was by flame ionisation.
- One cDNA ORF tested in this manner displayed a high level of elongase activity on the GLA substrate, converting 44% to DHGLA.
- the identity of this elongation product was confirmed as DHGLA by comparison with a known standard (the standards used were known standards for either DHGLA, AA, EPA or VA from Sigma Chemicals, Ltd.), using GCMS analysis using a Kratos MS80RFA (Napier, J. A., supra; Michaelson, L. V., supra; Michaelson, L. V., supra).
- the deduced amino acid sequence of the functional elongase clone identified it as being encoded by the C.
- elegans gene F56H11.4, and comparison with the yeast ELO genes showed low homology confined to a few short amino acid motifs (see Fig. 10).
- Some similarity with a mouse gene Cig30 (Tvrdik, P., (1997) J. Biol. Chem. 272, 31738-31746), which has been implicated in the recruitment of brown adipose tissue in liver tissue, was also observed, as well as a potential human homologue encoded by a gene located on chromosome 4q25, BAC 207d4. The most closely related C.
- elegans ORFs F41H10.8 (U61954) and F56H11.3 (Z68749) are also shown, as is part of a related human gene present on chromosome IV (present on BAC clone B207d4; AC004050).
- GenBank accession numbers are given for all sequences.
- the range of fatty acids synthesised by C. elegans can potentially require a number of different elongation reactions (Tanaka, T., (1996) Lipids 31, 1173-1178).
- the substrate-specificity of the F56H11.4 PUFA elongase was therefore determined using a range of exogenous ly supplied fatty acids. This revealed that GLA is the major substrate, with a number of other fatty acids being elongated at a lower efficiency (see Table 1). Although most of these substrates are polyunsaturated fatty acids, it was unexpectedly observed that palmitoleoic.
- PA 16:1 ⁇ 9
- VA vaccenic acid
- the C. elegans PUFA elongase ORF F56H11.4 maps to the top of chromosome IV (at 4.32 cM) with a related sequence (F56H11.3; 51 % similarity) located l,824bp downstream.
- Another C. elegans gene (F41H10.8) was also observed, which is present on chromosome IN, and which shows a slightly higher level (53%) of similarity to the PUFA elongase than F56H11.3 (see Fig. 10).
- the PUFA elongase F56H11.4 was expressed in yeast in conjunction with either the ⁇ 6 - or ⁇ 5 -fatty acid desaturases previously isolated and characterised by the inventor (Napier, J. A., supra; Michaelson, L. V., supra). Expression of the ⁇ 6 -fatty acid desaturase and F56H1 1.4 was carried out in the presence of two different substrates (LA or ALA) while the ⁇ -fatty acid desaturase and the elongase were expressed in the presence of GLA only.
- DHGLA is an n-6 fatty acid
- OTA-derived eicostetraenoic acid is an n-3 type
- Verification was also provided that the 20C PUFAs synthesised in the yeast expression system were generated by the ⁇ 6 -desaturation of 18C substrates which were subsequently elongated, as the ⁇ 6 -desaturase showed no activity on 20:2 or 20:3 substrates (see Table HI).
- C. elegans ORF sequence can be subcloned into a plant expression vector pJD330, which comprises a viral 35S promoter, and a Nos terminator.
- the resulting cassette or promoter/coding sequence/terminator can then be subcloned into the plant binary transformation vector pBin 19, and the resulting plasmid introduced into Agrobacterium tumefaciens.
- This Agrobacterium strain can then be used to transform Arabidopsis by the vacuum-infiltration of inflorescences, and the seeds harvested and plated onto selective media containing kanamycin.
- Fatty acid methyl ester analysis can be carried out as previously described.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Cette invention concerne un polypeptide isolé renfermant une élongase d'acides gras polyinsaturés à longue chaîne fonctionnelle (PUFA).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9906307 | 1999-03-18 | ||
GBGB9906307.5A GB9906307D0 (en) | 1999-03-18 | 1999-03-18 | Novel polypeptides |
GB0003869 | 2000-02-18 | ||
GB0003869A GB0003869D0 (en) | 2000-02-18 | 2000-02-18 | Elongase II |
PCT/GB2000/001035 WO2000055330A1 (fr) | 1999-03-18 | 2000-03-20 | Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1161542A1 true EP1161542A1 (fr) | 2001-12-12 |
Family
ID=26243677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00911091A Withdrawn EP1161542A1 (fr) | 1999-03-18 | 2000-03-20 | Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1161542A1 (fr) |
JP (1) | JP2002538826A (fr) |
AU (1) | AU3308500A (fr) |
CA (1) | CA2365096A1 (fr) |
NO (1) | NO20014542D0 (fr) |
WO (1) | WO2000055330A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403349B1 (en) * | 1998-09-02 | 2002-06-11 | Abbott Laboratories | Elongase gene and uses thereof |
GB0107510D0 (en) * | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
JP2004532638A (ja) * | 2001-06-05 | 2004-10-28 | エクセリクシス・インコーポレイテッド | p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法 |
WO2003078639A2 (fr) * | 2002-03-16 | 2003-09-25 | The University Of York | Enzymes d'expression de plantes transgeniques impliquees dans la biosynthese d'acides gras |
EP1654344B1 (fr) * | 2003-08-01 | 2018-10-17 | BASF Plant Science GmbH | Procede de production d'acides gras polyinsatures dans des organismes transgeniques |
CA2884237C (fr) | 2004-04-22 | 2020-09-08 | Commonwealth Scientific And Industrial Research Organisation | Synthese d'acides gras polyinsatures a chaine longue par des cellules de recombinaison |
ES2529572T3 (es) | 2004-04-22 | 2015-02-23 | Commonwealth Scientific And Industrial Research Organisation | Síntesis de ácidos grasos poliinsaturados de cadena larga por células recombinantes |
EP1766023B1 (fr) | 2004-06-04 | 2010-09-01 | Fluxome Sciences A/S | Cellules metaboliquement transformees pour la production d'acides gras polyinsaturates |
WO2008025068A1 (fr) | 2006-08-29 | 2008-03-06 | Commonwealth Scientific And Industrial Research Organisation | synthèse d'acides gras |
US7892792B2 (en) | 2008-06-27 | 2011-02-22 | Indian Institute Of Science | Cells expressing Pichia cytochrome C |
CA2743880C (fr) | 2008-11-18 | 2020-08-18 | James Robertson Petrie | Cellules recombinantes possedant une activite elongase a5 exogene et methodes de production d'acide docosapentaenoique |
HUE033766T2 (en) | 2012-06-15 | 2018-01-29 | Commw Scient Ind Res Org | Preparation of long chain polyunsaturated fatty acids in plant cells |
PE20170253A1 (es) | 2013-12-18 | 2017-04-14 | Nuseed Pty Ltd | Lipido que comprende acidos grasos poliinsaturados de cadena larga |
KR102527795B1 (ko) | 2014-06-27 | 2023-05-02 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | 도코사펜타에노산을 포함하는 지질 |
CN104920307B (zh) * | 2015-06-19 | 2018-01-26 | 安徽省农业科学院农业工程研究所 | 一种适用于单粒子微束装置的秀丽小杆线虫固定方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403349B1 (en) * | 1998-09-02 | 2002-06-11 | Abbott Laboratories | Elongase gene and uses thereof |
-
2000
- 2000-03-20 WO PCT/GB2000/001035 patent/WO2000055330A1/fr not_active Application Discontinuation
- 2000-03-20 EP EP00911091A patent/EP1161542A1/fr not_active Withdrawn
- 2000-03-20 CA CA002365096A patent/CA2365096A1/fr not_active Abandoned
- 2000-03-20 AU AU33085/00A patent/AU3308500A/en not_active Abandoned
- 2000-03-20 JP JP2000605748A patent/JP2002538826A/ja active Pending
-
2001
- 2001-09-18 NO NO20014542A patent/NO20014542D0/no unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0055330A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO20014542L (no) | 2001-09-18 |
JP2002538826A (ja) | 2002-11-19 |
NO20014542D0 (no) | 2001-09-18 |
WO2000055330A9 (fr) | 2002-08-29 |
WO2000055330A1 (fr) | 2000-09-21 |
CA2365096A1 (fr) | 2000-09-21 |
AU3308500A (en) | 2000-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dar et al. | The FAD2 gene in plants: occurrence, regulation, and role | |
Petrie et al. | Development of a Brassica napus (Canola) crop containing fish oil-like levels of DHA in the seed oil | |
WO2000055330A1 (fr) | Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans | |
Beaudoin et al. | Heterologous reconstitution in yeast of the polyunsaturated fatty acid biosynthetic pathway | |
Wallis et al. | Lipid biochemists salute the genome | |
Murata et al. | Acyl-lipid desaturases and their importance in the tolerance and acclimatization to cold of cyanobacteria. | |
Voelker et al. | Fatty acid biosynthesis redirected to medium chains in transgenic oilseed plants | |
Jin et al. | Characterization and temporal expression of a ω-6 fatty acid desaturase cDNA from sesame (Sesamum indicum L.) seeds | |
Zank et al. | Cloning and functional characterisation of an enzyme involved in the elongation of Δ6‐polyunsaturated fatty acids from the moss Physcomitrella patens | |
CA2519169C (fr) | Enzymes d'expression de plantes transgeniques impliquees dans la biosynthese d'acides gras | |
US7041872B2 (en) | Acyl CoA:cholesterol acyltransferase related nucleic acid sequences | |
US6489461B1 (en) | Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use | |
WO1999064616A2 (fr) | Acides gras polyinsatures dans des plantes | |
KR20220052373A (ko) | 장쇄 다중불포화 지방산을 포함하는 지질 | |
BRPI0413786B1 (pt) | vetor recombinante com atividade dessaturase e métodos de produzir óleo de semente com ácidos graxos ômega-3, de produzir ácido graxo ômega-3 e de produzir planta compreendendo óleo de semente com níveis alterados de ácidos graxos ômega-3 | |
CA2399349A1 (fr) | Nouveau gene d'elongase et procede de preparation d'acides gras a insaturation multiple | |
JP2009529890A (ja) | Pufaポリケチドシンターゼ系を用いた異種生物における多価不飽和脂肪酸の生産方法 | |
Bryant et al. | ACYL-ACYL CARRIER PROTEIN DESATURASE2 and 3 are responsible for making omega-7 fatty acids in the Arabidopsis aleurone | |
Claver et al. | Functional analysis of β-ketoacyl-CoA synthase from biofuel feedstock Thlaspi arvense reveals differences in the triacylglycerol biosynthetic pathway among Brassicaceae | |
CN106413389A (zh) | 通过破囊壶菌PUFA合酶在油料作物中产生ω‑3长链多不饱和脂肪酸 | |
CA2343969A1 (fr) | Nouvelles acyltransferases vegetales | |
Guan et al. | RNAi targeting putative genes in phosphatidylcholine turnover results in significant change in fatty acid composition in Crambe abyssinica seed oil | |
Lee et al. | Lesquerella FAD3-1 gene is responsible for the biosynthesis of trienoic acid and dienoic hydroxy fatty acids in seed oil | |
Beaudoin et al. | Production of C~ 2~ 0 polyunsaturated fatty acids (PUFAs) by pathway engineering: identification of a PUFA elongase component from Caenorhabditis elegans | |
Kim et al. | Functional characterization of polyunsaturated fatty acid delta 6-desaturase and elongase genes from the black seabream (Acanthopagrus schlegelii) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011005 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20050531 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051213 |